Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence

REFERENCES

• Appella, E., and C. W. Anderson. 2001. Post-translational modifications and activation of p53 by genotoxic stresses Eur. J. Biochem. 268: 2764–2772.
   Google Scholar
• Ashcroft, M., Y. Taya, and K. H. Vousden. 2000. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20: 3224–3233.
   PubMed Web of Science ®Google Scholar
• Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis, and S. L. Berger. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8: 1243–1254.
   PubMed Web of Science ®Google Scholar
• Berg, O. G., and P. H. von Hippel. 1987. Selection of DNA binding sites by regulatory proteins. Statistical-mechanical theory and application to operators and promoters. J. Mol. Biol. 193: 723–750.
   PubMed Web of Science ®Google Scholar
• Biggin, M. D. 2001. To bind or not to bind. Nat. Genet. 28: 303–304.
   PubMedGoogle Scholar
• Blattner, C., E. Tobiasch, M. Litfen, H. J. Rahmsdorf, and P. Herrlich. 1999. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18: 1723–1732.
   PubMed Web of Science ®Google Scholar
• Bourdon, J. C., V. Deguin-Chambon, J. C. Lelong, P. Dessen, P. May, B. Debuire, and E. May. 1997. Further characterisation of the p53 responsive element—identification of new candidate genes for trans-activation by p53. Oncogene 14: 85–94.
   PubMedGoogle Scholar
• Brachmann, R. K., M. Vidal, and J. D. Boeke. 1996. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci. USA 93: 4091–4095.
   PubMed Web of Science ®Google Scholar
• Brachmann, R. K., K. Yu, Y. Eby, N. P. Pavletich, and J. D. Boeke. 1998. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17: 1847–1859.
   PubMedGoogle Scholar
• Bullock, A. N., J. Henckel, and A. R. Fersht. 2000. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245–1256.
   PubMed Web of Science ®Google Scholar
• Campomenosi, P., P. Monti, A. Aprile, A. Abbondandolo, T. Frebourg, B. Gold, T. Crook, A. Inga, M. A. Resnick, R. Iggo, and G. Fronza. 2001. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573–3579.
   PubMed Web of Science ®Google Scholar
• Candau, R., D. M. Scolnick, P. Darpino, C. Y. Ying, T. D. Halazonetis, and S. L. Berger. 1997. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15: 807–816.
   PubMed Web of Science ®Google Scholar
• Chao, C., S. Saito, C. W. Anderson, E. Appella, and Y. Xu. 2000. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. USA 97: 11936–11941.
   PubMed Web of Science ®Google Scholar
• Chappuis, P. O., A. Estreicher, B. Dieterich, H. Bonnefoi, M. Otter, A. P. Sappino, and R. Iggo. 1999. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int. J. Cancer 84: 587–593.
   PubMedGoogle Scholar
• Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10: 2438–2451.
   PubMed Web of Science ®Google Scholar
• Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355.
   PubMed Web of Science ®Google Scholar
• Cosma, M. P., T. Tanaka, and K. Nasmyth. 1999. Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter. Cell 97: 299–311.
   PubMed Web of Science ®Google Scholar
• Di Como, C. J., and C. Prives. 1998. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16: 2527–2539.
   PubMedGoogle Scholar
• Dumaz, N., and D. W. Meek. 1999. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18: 7002–7010.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S. 1998. Regulation of p53 downstream genes. Semin. Cancer Biol. 8: 345–357.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1: 45–49.
   PubMed Web of Science ®Google Scholar
• Elkeles, A., T. Juven-Gershon, D. Israeli, S. Wilder, A. Zalcenstein, and M. Oren. 1999. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol. Cell. Biol. 19: 2594–2600.
   PubMed Web of Science ®Google Scholar
• Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8: 57–69.
   PubMed Web of Science ®Google Scholar
• Flaman, J. M., T. Frebourg, V. Moreau, F. Charbonnier, C. Martin, P. Chappuis, A. P. Sappino, I. M. Limacher, L. Bron, J. Benhattar, M. Tada, E. G. Van Meir, A. Estreicher, and R. D. Iggo. 1995. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA 92: 3963–3967.
   PubMed Web of Science ®Google Scholar
• Flatt, P. M., K. Polyak, L. J. Tang, C. D. Scatena, M. D. Westfall, L. A. Rubinstein, J. Yu, K. W. Kinzler, B. Vogelstein, D. E. Hill, and J. A. Pietenpol. 2000. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett. 156: 63–72.
   PubMedGoogle Scholar
• Flores, E. R., K. Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, and T. Jacks. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560–564.
   PubMed Web of Science ®Google Scholar
• Fogal, V., M. Gostissa, P. Sandy, P. Zacchi, T. Sternsdorf, K. Jensen, P. P. Pandolfi, H. Will, C. Schneider, and G. Del Sal. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19: 6185–6195.
   PubMed Web of Science ®Google Scholar
• Friedlander, P., Y. Haupt, C. Prives, and M. Oren. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16: 4961–4971.
   PubMed Web of Science ®Google Scholar
• Gietz, R. D., R. H. Schiestl, A. R. Willems, and R. A. Woods. 1995. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11: 355–360.
   PubMed Web of Science ®Google Scholar
• Greenblatt, M. S., P. O. Chappuis, J. P. Bond, N. Hamel, and W. D. Foulkes. 2001. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res. 61: 4092–4097.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
   PubMed Web of Science ®Google Scholar
• Hermeking, H., C. Lengauer, K. Polyak, T. C. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and B. Vogelstein. 1997. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1: 3–11.
   PubMed Web of Science ®Google Scholar
• Hoh, J., S. Jin, T. Parrado, J. Edington, A. J. Levine, and J. Ott. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA 99: 8467–8472.
   PubMed Web of Science ®Google Scholar
• Hovland, P., J. Flick, M. Johnston, and R. A. Sclafani. 1989. Galactose as a gratuitous inducer of GAL gene expression in yeasts growing on glucose. Gene 83: 57–64.
   PubMed Web of Science ®Google Scholar
• Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4: 865–875.
   PubMedGoogle Scholar
• Inga, A., P. Monti, G. Fronza, T. Darden, and M. A. Resnick. 2001. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20: 501–513.
   PubMedGoogle Scholar
• Inga, A., and M. A. Resnick. 2001. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20: 3409–3419.
   PubMedGoogle Scholar
• Ishioka, C., C. Englert, P. Winge, Y. X. Yan, M. Engelstein, and S. H. Friend. 1995. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 10: 1485–1492.
   PubMedGoogle Scholar
• Kaeser, M. D., and R. D. Iggo. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99: 95–100.
   PubMed Web of Science ®Google Scholar
• Kannan, K., N. Amariglio, G. Rechavi, J. Jakob-Hirsch, I. Kela, N. Kaminski, G. Getz, E. Domany, and D. Givol. 2001. DNA microarray identification of primary and secondary target genes regulated by p53. Oncogene 20: 2225–2234.
   PubMed Web of Science ®Google Scholar
• Kannan, K., N. Kaminski, G. Rechavi, J. Jakob-Hirsch, N. Amariglio, and D. Givol. 2001. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 20: 3449–3455.
   PubMedGoogle Scholar
• Kastan, M. B., Q. Zhan, W. S. el-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10: 1054–1072.
   PubMed Web of Science ®Google Scholar
• Lane, D. 2001. How cells choose to die. Nature 414: 25–27.
   PubMed Web of Science ®Google Scholar
• Lev Bar-Or, R., R. Maya, L. A. Segel, U. Alon, A. J. Levine, and M. Oren. 2000. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc. Natl. Acad. Sci. USA 97: 11250–11255.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88: 323–331.
   PubMed Web of Science ®Google Scholar
• Lieb, J. D., X. Liu, D. Botstein, and P. O. Brown. 2001. Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association. Nat. Genet. 28: 327–334.
   PubMed Web of Science ®Google Scholar
• Ludwig, R. L., S. Bates, and K. H. Vousden. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16: 4952–4960.
   PubMed Web of Science ®Google Scholar
• Luo, J., A. Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, and W. Gu. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137–148.
   PubMed Web of Science ®Google Scholar
• McLure, K. G., and P. W. Lee. 1998. How p53 binds DNA as a tetramer. EMBO J. 17: 3342–3350.
   PubMedGoogle Scholar
• Merika, M., and D. Thanos. 2001. Enhanceosomes. Curr. Opin. Genet. Dev. 11: 205–208.
   PubMed Web of Science ®Google Scholar
• Mundt, M., T. Hupp, M. Fritsche, C. Merkle, S. Hansen, D. Lane, and B. Groner. 1997. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 15: 237–244.
   PubMedGoogle Scholar
• Munsch, D., R. Watanabe-Fukunaga, J. C. Bourdon, S. Nagata, E. May, E. Yonish-Rouach, and P. Reisdorf. 2000. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J. Biol. Chem. 275: 3867–3872.
   PubMed Web of Science ®Google Scholar
• Nagaich, A. K., E. Appella, and R. E. Harrington. 1997. DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J. Biol. Chem. 272: 14842–14849.
   PubMed Web of Science ®Google Scholar
• Nagaich, A. K., D. Bhattacharyya, S. K. Brahmachari, and M. Bansal. 1994. CA/TG sequence at the 5′ end of oligo(A)-tracts strongly modulates DNA curvature. J. Biol. Chem. 269: 7824–7833.
   PubMed Web of Science ®Google Scholar
• Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. Tanaka. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053–1058.
   PubMed Web of Science ®Google Scholar
• Oda, K., H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori, K. Tamai, T. Tokino, Y. Nakamura, and Y. Taya. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862.
   PubMed Web of Science ®Google Scholar
• Oren, M. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274: 36031–36034.
   PubMed Web of Science ®Google Scholar
• Prives, C., and J. L. Manley. 2001. Why is p53 acetylated? Cell 107: 815–818.
   PubMed Web of Science ®Google Scholar
• Ptashne, M., and A. Gann. 1997. Transcriptional activation by recruitment. Nature 386: 569–577.
   PubMed Web of Science ®Google Scholar
• Ren, B., F. Robert, J. J. Wyrick, O. Aparicio, E. G. Jennings, I. Simon, J. Zeitlinger, J. Schreiber, N. Hannett, E. Kanin, T. L. Volkert, C. J. Wilson, S. P. Bell, and R. A. Young. 2000. Genome-wide location and function of DNA binding proteins. Science 290: 2306–2309.
   PubMed Web of Science ®Google Scholar
• Resnick-Silverman, L., S. St. Clair, M. Maurer, K. Zhao, and J. J. Manfredi. 1998. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev. 12: 2102–2107.
   PubMedGoogle Scholar
• Ronen, D., D. Schwartz, Y. Teitz, N. Goldfinger, and V. Rotter. 1996. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ. 7: 21–30.
   PubMedGoogle Scholar
• Saller, E., E. Tom, M. Brunori, M. Otter, A. Estreicher, D. H. Mack, and R. Iggo. 1999. Increased apoptosis induction by 121F mutant p53. EMBO J. 18: 4424–4437.
   PubMedGoogle Scholar
• Samuels-Lev, Y., D. J. O'Connor, D. Bergamaschi, G. Trigiante, J. K. Hsieh, S. Zhong, I. Campargue, L. Naumovski, T. Crook, and X. Lu. 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8: 781–794.
   PubMed Web of Science ®Google Scholar
• Scharer, E., and R. Iggo. 1992. Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res. 20: 1539–1545.
   PubMedGoogle Scholar
• Smith, P. D., S. Crossland, G. Parker, P. Osin, L. Brooks, J. Waller, E. Philp, M. R. Crompton, B. A. Gusterson, M. J. Allday, and T. Crook. 1999. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 18: 2451–2459.
   PubMed Web of Science ®Google Scholar
• Storici, F., L. K. Lewis, and M. A. Resnick. 2001. In vivo site-directed mutagenesis using oligonucleotides. Nat. Biotechnol. 19: 773–776.
   PubMed Web of Science ®Google Scholar
• Szak, S. T., D. Mays, and J. A. Pietenpol. 2001. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21: 3375–3386.
   PubMed Web of Science ®Google Scholar
• Tanaka, H., H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei, and Y. Nakamura. 2000. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42–49.
   PubMed Web of Science ®Google Scholar
• Thornborrow, E. C., and J. J. Manfredi. 1999. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J. Biol. Chem. 274: 33747–33756.
   PubMedGoogle Scholar
• Thukral, S. K., Y. Lu, G. C. Blain, T. S. Harvey, and V. L. Jacobsen. 1995. Discrimination of DNA binding sites by mutant p53 proteins. Mol. Cell. Biol. 15: 5196–5202.
   PubMedGoogle Scholar
• Tokino, T., S. Thiagalingam, W. S. el-Deiry, T. Waldman, K. W. Kinzler, and B. Vogelstein. 1994. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3: 1537–1542.
   PubMedGoogle Scholar
• Unger, T., T. Juven-Gershon, E. Moallem, M. Berger, R. Vogt Sionov, G. Lozano, M. Oren, and Y. Haupt. 1999. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18: 1805–1814.
   PubMed Web of Science ®Google Scholar
• Velasco-Miguel, S., L. Buckbinder, P. Jean, L. Gelbert, R. Talbott, J. Laidlaw, B. Seizinger, and N. Kley. 1999. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18: 127–137.
   PubMed Web of Science ®Google Scholar
• Venot, C., M. Maratrat, C. Dureuil, E. Conseiller, L. Bracco, and L. Debussche. 1998. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17: 4668–4679.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408: 307–310.
   PubMed Web of Science ®Google Scholar
• Wahl, G. M., and A. M. Carr. 2001. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell. Biol. 3: E277–E286.
   PubMed Web of Science ®Google Scholar
• Walker, D. R., J. P. Bond, R. E. Tarone, C. C. Harris, W. Makalowski, M. S. Boguski, and M. S. Greenblatt. 1999. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 18: 211–218.
   PubMedGoogle Scholar
• Wang, L., Q. Wu, P. Qiu, A. Mirza, M. McGuirk, P. Kirschmeier, J. R. Greene, Y. Wang, C. B. Pickett, and S. Liu. 2001. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J. Biol. Chem. 276: 43604–43610.
   PubMedGoogle Scholar
• Wang, T., T. Kobayashi, R. Takimoto, A. E. Denes, E. L. Snyder, W. S. el-Deiry, and R. K. Brachmann. 2001. hADA3 is required for p53 activity. EMBO. J. 20: 6404–6413.
   PubMed Web of Science ®Google Scholar
• Wieczorek, A. M., J. L. Waterman, M. J. Waterman, and T. D. Halazonetis. 1996. Structure-based rescue of common tumor-derived p53 mutants. Nat. Med. 2: 1143–1146.
   PubMedGoogle Scholar
• Xu, J., and G. F. Morris. 1999. p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol. Cell. Biol. 19: 12–20.
   PubMed Web of Science ®Google Scholar
• Yu, J., L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein. 2001. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7: 673–682.
   PubMed Web of Science ®Google Scholar
• Yu, J., L. Zhang, P. M. Hwang, C. Rago, K. W. Kinzler, and B. Vogelstein. 1999. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. USA 96: 14517–14522.
   PubMed Web of Science ®Google Scholar
• Zauberman, A., D. Flusberg, Y. Haupt, Y. Barak, and M. Oren. 1995. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 23: 2584–2592.
   PubMed Web of Science ®Google Scholar
• Zauberman, A., A. Lupo, and M. Oren. 1995. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene 10: 2361–2366.
   PubMedGoogle Scholar
• Zhao, R., K. Gish, M. Murphy, Y. Yin, D. Notterman, W. H. Hoffman, E. Tom, D. H. Mack, and A. J. Levine. 2000. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14: 981–993.
   PubMedGoogle Scholar
• Zhu, J., S. Zhang, J. Jiang, and X. Chen. 2000. Definition of the p53 functional domains necessary for inducing apoptosis. J. Biol. Chem. 275: 39927–39934.
   PubMed Web of Science ®Google Scholar